Allogeneic adipose-derived stem cells with low immunogenicity constructing tissue-engineered bone for repairing bone defects in pigs
- PMID: 22963757
- DOI: 10.3727/096368912X654966
Allogeneic adipose-derived stem cells with low immunogenicity constructing tissue-engineered bone for repairing bone defects in pigs
Abstract
The ideal cells for tissue engineering should have the following characteristics: easy obtainment, safety, immune privilege, the capability of self-renewal, and multipotency. Adipose-derived stem cells (ADSCs) are a promising candidate. However, the immunogenicity of allogeneic mesenchymal stem cells limits their long-term benefits. In this study, we introduced human cytomegalovirus US2/US3 gene into the ADSCs to decrease the expression of MHC I protein of ADSCs and reduce the activation of T-cells of the recipient animals. Moreover, the biosafety and biological characteristics of ADSCs transfected with the US2/US3 genes (ADSCs-US2/US3) were similar to normal ADSCs. Then we took ADSCs-US2/US3 to construct a tissue-engineered bone for repairing bone defects in pigs and found that there were no great differences in repair effects or healing time between the allogeneic ADSCs-US2/US3 group and the autologous ADSC group. These results suggest that allogeneic ADSCs-US2/US3 have the advantages of biological safety, low immunogenicity, and effective osteogenesis. Such barely immunogenic ADSCs will be crucial for the success of future tissue-regenerative approaches.
Similar articles
-
Repair of bone defects in rat radii with a composite of allogeneic adipose-derived stem cells and heterogeneous deproteinized bone.Stem Cell Res Ther. 2018 Mar 27;9(1):79. doi: 10.1186/s13287-018-0817-1. Stem Cell Res Ther. 2018. PMID: 29587852 Free PMC article.
-
Mesenchymal stem cells engineered to inhibit complement-mediated damage.PLoS One. 2013;8(3):e60461. doi: 10.1371/journal.pone.0060461. Epub 2013 Mar 26. PLoS One. 2013. PMID: 23555976 Free PMC article.
-
Human cytomegalovirus US3 chimeras containing US2 cytosolic residues acquire major histocompatibility class I and II protein degradation properties.J Virol. 2003 Apr;77(8):4731-8. doi: 10.1128/jvi.77.8.4731-4738.2003. J Virol. 2003. PMID: 12663780 Free PMC article.
-
[RESEARCH PROGRESS OF CONSTRUCTING INJECTABLE TISSUE ENGINEERED ADIPOSE TISSUE WITH ADIPOSE-DERIVED STEM CELLS].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2015 Feb;29(2):245-9. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2015. PMID: 26455158 Review. Chinese.
-
Adipose-derived mesenchymal stem cells and regenerative medicine.Dev Growth Differ. 2013 Apr;55(3):309-18. doi: 10.1111/dgd.12049. Epub 2013 Mar 3. Dev Growth Differ. 2013. PMID: 23452121 Review.
Cited by
-
Stem cell therapy for bone repair: a systematic review and meta-analysis of preclinical studies with large animal models.Br J Clin Pharmacol. 2014 Oct;78(4):718-26. doi: 10.1111/bcp.12382. Br J Clin Pharmacol. 2014. PMID: 24645974 Free PMC article.
-
Advances in regenerative therapy: A review of the literature and future directions.Regen Ther. 2020 Feb 20;14:136-153. doi: 10.1016/j.reth.2020.01.004. eCollection 2020 Jun. Regen Ther. 2020. PMID: 32110683 Free PMC article. Review.
-
Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing.Biomaterials. 2019 May;203:96-110. doi: 10.1016/j.biomaterials.2018.06.026. Epub 2018 Jun 22. Biomaterials. 2019. PMID: 29980291 Free PMC article. Review.
-
Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?Stem Cell Res Ther. 2014 Aug 19;5(4):99. doi: 10.1186/scrt488. Stem Cell Res Ther. 2014. PMID: 25158057 Free PMC article. Review.
-
Proliferation and differentiation of human adipose-derived mesenchymal stem cells (ASCs) into osteoblastic lineage are passage dependent.Inflamm Res. 2014 Nov;63(11):907-17. doi: 10.1007/s00011-014-0764-y. Epub 2014 Aug 7. Inflamm Res. 2014. PMID: 25098205
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials